home.social

#rasmutations — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #rasmutations, aggregated by home.social.

  1. European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

    Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
    #NewsBeep #News #Medication #CA #Canada #daraxonrasib #ema #FDA #Health #Inc. #NationalPriorityVoucher #PancreaticCancer #patients #pilotprogram #RASmutations #RevolutionMedicines
    newsbeep.com/ca/788340/

  2. European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

    Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #Daraxonrasib #ema #FDA #Health #Inc. #NationalPriorityVoucher #pancreaticcancer #patients #Pilotprogram #RASmutations #RevolutionMedicines
    newsbeep.com/us/750531/

  3. European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

    Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
    #NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #Daraxonrasib #ema #FDA #Health #Inc. #NationalPriorityVoucher #pancreaticcancer #patients #Pilotprogram #RASmutations #RevolutionMedicines
    newsbeep.com/us/750531/

  4. European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

    Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
    #Europe #EU #daraxonrasib #EMA #European #FDA #Inc. #NationalPriorityVoucher #pancreaticcancer #Patients #pilotprogram #RASmutations #RevolutionMedicines
    europesays.com/europe/88500/

  5. European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

    Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
    #Europe #EU #daraxonrasib #EMA #European #FDA #Inc. #NationalPriorityVoucher #pancreaticcancer #Patients #pilotprogram #RASmutations #RevolutionMedicines
    europesays.com/europe/88482/